Related Experiment Video
Updated: Jun 17, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Deciphering the Effect of a Cu(II)-hydrazone Complex on Intracellular Cell Signalling Pathways in a Human
Lucía M Balsa1, Lucía Santa Maria de la Parra1, Valeria Ferretti1
1CEQUINOR (UNLP, CCT-CONICET La Plata, asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Blvd. 120 N° 1465, La Plata, (1900), Argentina.
Abstract:
New therapeutic strategies for osteosarcoma (OS) have demonstrated the potential efficacy of copper compounds as anticancer drugs and as a substitute for the often used platinum compounds. OS is a type of bone cancer, primarily affecting young adults and children.The main objective of this work is to discover the molecular targets and cellular pathways related to the antitumor properties of a Cu(II)-hydrazone toward human OS 2D and 3D systems. Cell viability study using MG-63 cells was evaluated in OS monolayer and spheroids. CuHL significantly reduced cell viability in OS models (IC50 2D: 2.6±0.3 μM; IC50 3D: 9.9±1.4 μM) (p<0.001). Also, CuHL inhibits cell proliferation and it induces cells to apoptosis. The main mechanism of action found for CuHL are the interaction with DNA, genotoxicity, the ROS generation and the proteasome activity inhibition. Besides, 67 differentially expressed proteins were found using proteomic approaches. Of those 67 proteins, 40 were found overexpressed and 27 underexpressed. The response to stress and to unfolded protein, as well as ATP synthesis were the most affected biological process among upregulated proteins, whilst proteins related to DNA replication and redox homeostasis were downregulated.
Insights
Copper compounds show promise as osteosarcoma (OS) treatments, effectively reducing cancer cell viability and proliferation. This study reveals copper-hydrazone
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Osteosarcoma (OS) is a bone cancer predominantly affecting young individuals.
- Copper compounds are emerging as potential anticancer agents, offering an alternative to platinum-based therapies.
- Understanding the molecular mechanisms of novel copper-based drugs is crucial for therapeutic development.
Purpose of the Study:
- To elucidate the molecular targets and cellular pathways of a copper(II)-hydrazone (CuHL) against human osteosarcoma.
- To evaluate the efficacy of CuHL in both 2D and 3D osteosarcoma models.
- To identify key protein expression changes induced by CuHL treatment.
Main Methods:
- Cell viability assays were performed on MG-63 osteosarcoma cells in 2D and 3D cultures.
- Mechanisms of action including DNA interaction, genotoxicity, reactive oxygen species (ROS) generation, and proteasome activity were investigated.
- Proteomic analysis was employed to identify differentially expressed proteins.
Main Results:
- CuHL significantly reduced osteosarcoma cell viability in 2D (IC50: 2.6±0.3 μM) and 3D (IC50: 9.9±1.4 μM) models.
- CuHL inhibited cell proliferation and induced apoptosis.
- Key mechanisms involved DNA interaction, genotoxicity, ROS generation, and proteasome inhibition.
- Proteomic analysis identified 67 differentially expressed proteins, impacting stress response, unfolded protein response, ATP synthesis, DNA replication, and redox homeostasis.
Conclusions:
- The copper(II)-hydrazone (CuHL) exhibits significant antitumor activity against osteosarcoma cells.
- CuHL exerts its effects through multiple pathways including DNA damage, oxidative stress, and proteasome inhibition.
- Proteomic data provides insights into the molecular underpinnings of CuHL's efficacy, highlighting its potential as a novel osteosarcoma therapeutic.
